Rúa-Figueroa, IñigoRúa-Figueroa, DavidPérez-Veiga, NataliaAnzola, Ana MGalindo-Izquierdo, MaríaCalvo-Alén, JaimeFernández-Nebro, AntonioSangüesa, ClaraMenor-Almagro, RaúlTomero, EvaDel Val, NatividadUriarte-Isazelaya, EstherBlanco, RicardoAndreu, José LBoteanu, AlinaNarváez, JavierCobo, TatianaBohórquez, CristinaMontilla, CarlosSalas, EstebanToyos, Francisco JBernal, José ASalgado, EvaFreire, MercedesMas, Antonio JExpósito, LorenaHernández-Beriain, José AIbarguengoitia, OihaneVelloso-Feijoo, María LLozano-Rivas, NuriaBonilla, GemmaMoreno, MireiaJiménez, InmaculadaQuevedo-Vila, VíctorPecondón, AngelaAurrecoechea, ElenaValls, EliaMouriño, CoralVázquez-Rodríguez, TomásPego-Reigosa, José M2023-05-032023-05-032022-01-02http://hdl.handle.net/10668/22513Factors associated with chronic heart failure (CHF) in patients with systemic lupus erythematosus (SLE) have received little attention. Recent data on the use of hydroxychloroquine in the treatment of SARS-CoV-2 infection have cast doubt on its cardiac safety. The factors associated with CHF, including therapy with antimalarials, were analyzed in a large multicenter SLE cohort. Cross-sectional study including all patients with SLE (ACR-1997 criteria) included in the Spanish Society of Rheumatology Lupus Register (RELESSER), based on historically gathered data. Patients with CHF prior to diagnosis of SLE were excluded. A multivariable analysis exploring factors associated with CHF was conducted. The study population comprised 117 patients with SLE (ACR-97 criteria) and CHF and 3,506 SLE controls. Ninety percent were women. Patients with CHF were older and presented greater SLE severity, organ damage, and mortality than those without CHF. The multivariable model revealed the factors associated with CHF to be ischemic heart disease (7.96 [4.01-15.48], p  Patients with SLE and CHF experience more severe SLE. Treatment with antimalarials appears to confer a cardioprotective effect.enAntimalarialsChronic heart failureSystemic lupus erythematosusAntimalarialsCOVID-19Cross-Sectional StudiesFemaleHeart FailureHumansLupus Erythematosus, SystemicRegistriesRheumatologySARS-CoV-2research article35033377open access10.1016/j.semarthrit.2021.11.0121532-866XPMC8720299https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720299https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720299/pdf